Novartis Starts Phase 2 Psoriatic Arthritis Study
The clinical trial evaluates a new molecular glue degrader for patients with moderate to severe psoriatic arthritis.
Updated on Oct. 28, 2026 in Arthritis
Live Poll
Do you trust that large-scale corporate pharmaceutical partnerships prioritize patient health over financial gain?
Novartis has officially initiated a Phase 2 clinical study of MRT-6160, a VAV1-directed molecular glue degrader, for patients diagnosed with active moderate to severe psoriatic arthritis. As part of this advancement, Monte Rosa Therapeutics will receive a $37.5 million milestone payment.
Why it matters
The trial aims to determine the efficacy, safety, tolerability, and dose-response relationship of the drug in a clinical setting. This study represents a key step for Novartis in its exclusive global development and commercialization of the potential therapy.
The study, designated as NCT07801495, evaluates MRT-6160 in patients with active moderate to severe psoriatic arthritis. Monte Rosa is eligible for up to $2.1 billion in total milestone payments throughout the drug's development and commercial lifecycle.
The players
Novartis
This Swiss multinational pharmaceutical company is responsible for funding and conducting the clinical studies for MRT-6160.
Monte Rosa Therapeutics
Headquartered in Boston, this biotechnology company focuses on developing molecular glue degraders to treat various immune-mediated diseases.
The details
The trial is structured as a randomized, double-blind, placebo-controlled, multicenter Phase 2a/b study funded and led by Novartis. Monte Rosa retains a 30% profit and loss share arrangement for the therapy in the United States.
Timeline
August 2026: Phase 2 trial for Sjögren's disease was initiated.
October 28, 2026: The initiation of the psoriatic arthritis study was announced.
The Big Picture
This study is registered on the clinical trial study information portal, allowing researchers and the public to monitor the progress of VAV1-directed molecular glue degraders. This reflects a broader shift in pharmaceutical innovation toward targeted protein degradation therapies for immune-mediated conditions.
The initiation of this Phase 2 trial provides a future potential treatment option for those currently suffering from moderate to severe psoriatic arthritis. Patients interested in experimental therapies may track the progress of this trial through public clinical registries as data becomes available.
The takeaway
This trial marks a significant milestone in the development of molecular glue degraders for systemic immune conditions. Future research efforts will continue to expand investigations into how these therapies perform across a range of immune-mediated diseases.
Further reading
For more on current research, visit the Arthritis section.
More information
Access study protocols and participant eligibility requirements at the clinical trial study information portal.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that large-scale corporate pharmaceutical partnerships prioritize patient health over financial gain?
